SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Science soars on getting EIR from USFDA for Bangalore facility

30 Mar 2020 Evaluate
Strides Pharma Science is currently trading at Rs. 312.10, up by 4.10 points or 1.33% from its previous closing of Rs. 308.00 on the BSE.

The scrip opened at Rs. 324.00 and has touched a high and low of Rs. 324.00 and Rs. 310.45 respectively. So far 10002 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 547.35 on 14-Feb-2020 and a 52 week low of Rs. 271.00 on 20-Mar-2020.

Last one week high and low of the scrip stood at Rs. 346.40 and Rs. 274.00 respectively. The current market cap of the company is Rs. 2807.88 crore.

The promoters holding in the company stood at 31.28%, while Institutions and Non-Institutions held 47.24% and 21.48% respectively.

Strides Pharma Science has received the Establishment Inspection Report (EIR) for the inspection conducted by the USFDA in January 2020 at Company’s flagship facility KRS Gardens, Bangalore. The inspection was related to specific Extended Release applications made from the site. Receipt of EIR confirms the successful closure of the inspections. 

The flagship facility in Bangalore is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

1068.05 -2.85 (-0.27%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×